Evolent Health, Inc. announced changes to its Board of Directors, with Richard 'Rick' Jelinek slated to be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott. Mr. Jelinek joined the Board as an independent director in 2023 and previously served as Executive Vice President of CVS Health.
Additionally, Brendan Springstubb has joined the Evolent Board as an independent director, bringing over 20 years of experience investing in healthcare companies. Mr. Springstubb was previously a Principal at Engaged Capital, one of Evolent's largest shareholders.
These appointments are part of the company's ongoing commitment to strong corporate governance and board refreshment efforts. The Board intends to refresh an additional independent director seat in advance of the 2025 Annual Meeting, marking five new independent directors added in the past three years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.